Drug Pricing

Pharmalot By Ed Silverman

Health Canada releases final version of controversial regulations for controlling drug prices

First Opinion By Ekaterina Cleary

Remdesivir’s hefty price tag ignores NIH investment in its creation

Politics By Lev Facher

As election nears, Trump leans on health care agencies to aid his campaign

D.C. Diagnosis By Nicholas Florko

Will this be the most-watched FDA meeting ever?

Pharmalot By Ed Silverman

Insulin in the U.S. cost up to 10 times more than in nearly three dozen other OECD countries

Pharmalot By Ed Silverman

What doubts? New forecast says biosimilars will cut U.S. drug spending by $100 billion in five years

Politics By Nicholas Florko

‘Are you an American, sir?’: Lawmakers interrogate Amgen, Novartis, Mallinckrodt executives on why U.S. prices are so high

Pharmalot By Ed Silverman

Pharmalittle: FDA extends probe into AstraZeneca Covid-19 vaccine; House committee blasts pharma CEOs over prices

Politics By Nicholas Florko

‘You just got better at making money’: Democrats blast Celgene, Teva for price hikes detailed in internal documents

Pharmalot By Ed Silverman

For the first time, drug makers and PBMs must jointly face an insulin price fixing lawsuit

Politics By Nicholas Florko

Congressional investigation reveals Celgene, Teva plotted to keep drug prices high

Pharma By Ed Silverman

Pharmalittle: Biden getting more pharma donations than Trump; FDA safety plan not ‘well suited’ for opioids

Politics By Nicholas Florko

Drug industry CEOs will testify this week about some of pharma’s most controversial medicines

Pharmalot By Ed Silverman

With a new law, California becomes the first state to pursue its own line of generics

President Trump Delivers Remarks On His Healthcare Policies In North Carolina

Politics By Nicholas Florko and Lev Facher

Republicans blasted Obama’s use of an obscure Medicare law. Now Trump’s using it on $200 drug coupons — and the GOP is silent

First Opinion By Edward Abrahams

Personalized medicine is the future of health care. Two Trump administration proposals could stymie it

Pharmalot By Ed Silverman

Gilead to pay $97 million for allegedly using a charity to pay kickbacks to Medicare patients

Pharma By Ed Silverman

HHS criticizes Lilly for seeking to curtail discounts for safety-net hospitals

Pharmalot By Ed Silverman

Public funding underwrote much of the development of J&J’s drug for TB, analysis finds

Pharmalot By Ed Silverman

Novartis sells bonds tied to expanding access to medicines in poor countries

Pharmalot By Ed Silverman

State treasurers urge Gilead to lower the price of remdesivir and not pursue “unreasonable profits”

Politics By Lev Facher

Biden-aligned group outlines potential Day 1 drug pricing actions

Pharmalot By Ed Silverman

The cost of Gilead’s HIV prevention pill thwarted widespread use, study finds

Pharmalot By Ed Silverman

Lawmakers demand drug makers stop threatening to end discounts for safety-net hospitals

Politics By Nicholas Florko and Lev Facher

Most Read

Trump claims his policies made insulin ‘so cheap, it’s like water.’ But for most people, it costs just as much as before

AstraZeneca loses first-of-its-kind lawsuit filed by Dutch insurer over patent maneuver

When off-label may mean off-target: How would doctors and insurers navigate demand for a new, narrow Alzheimer’s drug?

I have spinal muscular atrophy. Critics of the $2 million new gene therapy are missing the point

9 ways Covid-19 may forever upend the U.S. health care industry

Trump promises seniors $200 prescription drug gift certificates, but questions abound

Trump’s ‘most favored nation’ executive order on drug prices is a scam for seniors

Why didn’t nonprofits and the NIH require ‘reasonable’ pricing for Zolgensma? That may happen in France

All Coverage

Health Canada releases final version of controversial regulations for controlling drug prices

Remdesivir’s hefty price tag ignores NIH investment in its creation

As election nears, Trump leans on health care agencies to aid his campaign

Will this be the most-watched FDA meeting ever?

Insulin in the U.S. cost up to 10 times more than in nearly three dozen other OECD countries

What doubts? New forecast says biosimilars will cut U.S. drug spending by $100 billion in five years

‘Are you an American, sir?’: Lawmakers interrogate Amgen, Novartis, Mallinckrodt executives on why U.S. prices are so high

Pharmalittle: FDA extends probe into AstraZeneca Covid-19 vaccine; House committee blasts pharma CEOs over prices

‘You just got better at making money’: Democrats blast Celgene, Teva for price hikes detailed in internal documents

For the first time, drug makers and PBMs must jointly face an insulin price fixing lawsuit

Congressional investigation reveals Celgene, Teva plotted to keep drug prices high

Pharmalittle: Biden getting more pharma donations than Trump; FDA safety plan not ‘well suited’ for opioids

Drug industry CEOs will testify this week about some of pharma’s most controversial medicines

With a new law, California becomes the first state to pursue its own line of generics

Republicans blasted Obama’s use of an obscure Medicare law. Now Trump’s using it on $200 drug coupons — and the GOP is silent

Personalized medicine is the future of health care. Two Trump administration proposals could stymie it

Gilead to pay $97 million for allegedly using a charity to pay kickbacks to Medicare patients

HHS criticizes Lilly for seeking to curtail discounts for safety-net hospitals

Public funding underwrote much of the development of J&J’s drug for TB, analysis finds

Novartis sells bonds tied to expanding access to medicines in poor countries

State treasurers urge Gilead to lower the price of remdesivir and not pursue “unreasonable profits”

Biden-aligned group outlines potential Day 1 drug pricing actions

The cost of Gilead’s HIV prevention pill thwarted widespread use, study finds

Lawmakers demand drug makers stop threatening to end discounts for safety-net hospitals

Trump’s last-ditch drug pricing moves could help him in November. But they likely won’t save Americans money